These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 28199076)

  • 21. Symptom score change and patient versus doctor satisfaction in overactive bladder before and after anti-muscarinic treatment.
    Bunyavejchevin S
    J Obstet Gynaecol Res; 2015 Jun; 41(6):957-61. PubMed ID: 25773663
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The impact of Mirabegron on sexual function in women with idiopathic overactive bladder.
    Gubbiotti M; Giannantoni A; Cantaluppi S; Coluccia AC; Ghezzi F; Serati M
    BMC Urol; 2019 Jan; 19(1):7. PubMed ID: 30665388
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The combination of herbal medicine Weng-li-tong with Tolterodine may be better than Tolterodine alone in the treatment of overactive bladder in women: a randomized placebo-controlled prospective trial.
    Xiao DD; Lv JW; Xie X; Jin XW; Lu MJ; Shao Y
    BMC Urol; 2016 Aug; 16(1):49. PubMed ID: 27503124
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The effect of overactive bladder treatment with anticholinergics on female sexual function in women: a prospective observational study.
    Cakir SS; Degirmentepe RB; Atalay HA; Canat HL; Ozbir S; Culha MG; Polat EC; Otunctemur A
    Int Urol Nephrol; 2019 Jan; 51(1):27-32. PubMed ID: 30448887
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Low-dose Desmopressin and Tolterodine Combination Therapy for Treating Nocturia in Women with Overactive Bladder: A Double-blind, Randomized, Controlled Study.
    Rovner ES; Raymond K; Andruczyk E; Juul KV
    Low Urin Tract Symptoms; 2018 Sep; 10(3):221-230. PubMed ID: 28560762
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Percutaneous Tibial Nerve Stimulation Improves Female Sexual Function in Women With Overactive Bladder Syndrome.
    Musco S; Serati M; Lombardi G; Lumi E; Parisi AI; Del Popolo G; Finazzi Agrò E
    J Sex Med; 2016 Feb; 13(2):238-42. PubMed ID: 26803455
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clinical safety, tolerability and efficacy of combination tolterodine/pilocarpine in patients with overactive bladder.
    Dmochowski RR; Staskin DR; Duchin K; Paborji M; Tremblay TM
    Int J Clin Pract; 2014 Aug; 68(8):986-94. PubMed ID: 24666884
    [TBL] [Abstract][Full Text] [Related]  

  • 28. OnabotulinumtoxinA detrusor injection improves female sexual function in women with overactive bladder wet syndrome.
    Balzarro M; Rubilotta E; Braga A; Bassi S; Processali T; Artibani W; Serati M
    Eur J Obstet Gynecol Reprod Biol; 2018 Jun; 225():228-231. PubMed ID: 29753213
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparison of the efficacy and safety of tolterodine 2 mg and 4 mg combined with an α-blocker in men with lower urinary tract symptoms (LUTS) and overactive bladder: a randomized controlled trial.
    Kim TH; Jung W; Suh YS; Yook S; Sung HH; Lee KS
    BJU Int; 2016 Feb; 117(2):307-15. PubMed ID: 26305143
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Efficacy of solifenacin in patients previously treated with tolterodine extended release 4 mg: results of a 12-week, multicenter, open-label, flexible-dose study.
    Chancellor MB; Zinner N; Whitmore K; Kobashi K; Snyder JA; Siami P; Karram M; Laramée C; Capo' JP; Seifeldin R; Forero-Schwanhaeuser S; Nandy I
    Clin Ther; 2008 Oct; 30(10):1766-81. PubMed ID: 19014833
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Tolterodine activates the prefrontal cortex during bladder filling in OAB patients: a real-time NIRS-urodynamics study.
    Sakakibara ; Tateno F; Yano M; Takahashi O; Sugiyama M; Ogata T; Kishi M; Tsuyusaki Y; Yamamoto T; Uchiyama T; Yamanishi T; Shibata C
    Neurourol Urodyn; 2014 Sep; 33(7):1110-5. PubMed ID: 24038213
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Psychometric assessment of female overactive bladder syndrome and antimuscarinics-related effects.
    Hsiao SM; Liao SC; Chen CH; Chang TC; Lin HH
    Maturitas; 2014 Dec; 79(4):428-34. PubMed ID: 25238744
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Tolterodine treatment of women with overactive bladder syndrome: Comparison of night-time and daytime dosing for nocturia.
    Tsai KH; Hsiao SM; Lin HH
    J Obstet Gynaecol Res; 2017 Nov; 43(11):1719-1725. PubMed ID: 28714288
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effectiveness and tolerability of extended-release oxybutynin vs extended-release tolterodine in women with or without prior anticholinergic treatment for overactive bladder.
    Anderson RU; MacDiarmid S; Kell S; Barada JH; Serels S; Goldberg RP
    Int Urogynecol J Pelvic Floor Dysfunct; 2006 Sep; 17(5):502-11. PubMed ID: 16724169
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Tolterodine and tamsulosin for treatment of men with lower urinary tract symptoms and overactive bladder: a randomized controlled trial.
    Kaplan SA; Roehrborn CG; Rovner ES; Carlsson M; Bavendam T; Guan Z
    JAMA; 2006 Nov; 296(19):2319-28. PubMed ID: 17105794
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cost effectiveness of mirabegron compared with tolterodine extended release for the treatment of adults with overactive bladder in the United Kingdom.
    Aballéa S; Maman K; Thokagevistk K; Nazir J; Odeyemi IA; Hakimi Z; Garnham A; Toumi M
    Clin Drug Investig; 2015 Feb; 35(2):83-93. PubMed ID: 25491433
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Extended-release tolterodine with or without tamsulosin in men with lower urinary tract symptoms and overactive bladder: effects on urinary symptoms assessed by the International Prostate Symptom Score.
    Kaplan SA; Roehrborn CG; Chancellor M; Carlsson M; Bavendam T; Guan Z
    BJU Int; 2008 Nov; 102(9):1133-9. PubMed ID: 18510659
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Tolterodine extended release is efficacious in continent and incontinent subjects with overactive bladder.
    Rovner ES; Rackley R; Nitti VW; Wang JT; Guan Z;
    Urology; 2008 Sep; 72(3):488-93. PubMed ID: 18639327
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Therapeutic benefit in patients switching tolterodine to other novel antimuscarinic agents.
    Sánchez-Ballester F; Miranda P; Lizarraga I; Rejas J; Arumi D
    Actas Urol Esp; 2014 Apr; 38(3):156-63. PubMed ID: 24119382
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A prospective observational study of the effects of treatment with extended-release tolterodine on health-related quality of life of patients suffering overactive bladder syndrome in Sweden.
    Peeker R; Samsioe G; Kowalski J; Andersson AS; Bergqvist A
    Scand J Urol Nephrol; 2010 Apr; 44(3):138-46. PubMed ID: 20367449
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.